The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) a single institution experience of TRUST a worldwide open label non randomized phase IV trial - Stockholm 2007

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Stockholm 2007

Therapy of lung cancer

Chair(s): C. Brambilla (Grenoble, France), J. Vansteenkiste (Leuven, Belgium)

Session type: Oral Presentation

The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) a single institution experience of TRUST a worldwide open label non randomized phase IV trial

D. F. Heigener, M. Reck, D. Gerding, U. Gatzemeier (Grosshansdorf, Germany)

EVENTS HOME

Limited Access

Please log in to myERS to view this content.

Don't have a myERS account? Register

Note: consult the ERS Respiratory Channel access rights page for more details.

CDN Connection Issue

The ERS International Congress 2007, Stockholm

Limited Access

#{title}